Systematic review about breast cancer incidence in relation to hormone replacement therapy use

References

• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–4
   PubMed Web of Science ®Google Scholar
• Hemminki E, Kyyronen P, Pukkala E. Postmenopausal hormone drugs and breast and colon cancer: nordic countries 1995–2005. Maturitas 2008;61:299–304
   PubMed Web of Science ®Google Scholar
• Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 2008;372:608–10
   PubMed Web of Science ®Google Scholar
• Verkooijen HM, Koot VC, Fioretta G, et al. Hormone replacement therapy, mammography screening and changing age- specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 2008;107:389–95
   PubMed Web of Science ®Google Scholar
• Canfell K, Banks E, Clements M, et al. Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat 2009;117:671–3
   PubMed Web of Science ®Google Scholar
• Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A. Trends in hormone therapy and breast cancer incidence – results from the German Network of Cancer Registries. Pathobiology 2009;76:90–7
   PubMed Web of Science ®Google Scholar
• Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?Eur J Cancer 2009;45:1649–53
   PubMed Web of Science ®Google Scholar
• Seradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 2009;96:E1–6
   PubMedGoogle Scholar
• Lambe M, Wigertz A, Holmqvist M, et al. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 2010;121:679–83
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al.; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114:448–54
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?J Clin Oncol 2009;27:5138–43
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009:113:65–73
   PubMed Web of Science ®Google Scholar
• Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004;328:921–4
   PubMed Web of Science ®Google Scholar
• Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24:e49–50
   PubMed Web of Science ®Google Scholar
• Allemand H, Seradour B, Weill A, Ricordeau P. Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer 2008;95:11–15
   PubMed Web of Science ®Google Scholar
• Canfell K, Banks E, Moa A, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008;188:641–4
   PubMed Web of Science ®Google Scholar
• Brewster DH, Sharpe KH, Clark DI, Collins J. Declining breast cancer incidence and decreased HRT use. Lancet 2009;373: 459–60
   PubMed Web of Science ®Google Scholar
• Neutel CI, Morrison H. Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian women. Can J Public Health 2010;101:405–9
   PubMed Web of Science ®Google Scholar
• Antoine C, Ameye L, Moreau M, Paesmans M, Rozenberg S. Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium. Climacteric 2011;14: 464–71
   PubMed Web of Science ®Google Scholar
• Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway – explained by hormone therapy or mammographic screening?Int J Cancer 2012;130:2930–8
   PubMed Web of Science ®Google Scholar
• Ponti A, Rosso S, Zanetti R, Ricceri F, Tomatis M, Segnan N. Re: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1817–18
   PubMed Web of Science ®Google Scholar
• Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107:427–30
   PubMed Web of Science ®Google Scholar
• Vankrunkelsven P, Kellen E, Lousbergh D, et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 2009;118:425–32
   PubMed Web of Science ®Google Scholar
• Renard F, Vankrunkelsven P, Van Eycken L, Henau K, Boniol M, Autier P. Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 2010;21:2356–60
   PubMed Web of Science ®Google Scholar
• Daubisse-Marliac L, Delafosse P, Boitard JB, Poncet F, Grosclaude P, Colonna M. Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries. Ann Oncol 2011;22:329–34
   PubMed Web of Science ®Google Scholar
• Keegan TH, Chang ET, John EM, et al. Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004. Breast Cancer Res 2007;9:R62
   PubMedGoogle Scholar
• Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007;25:3437–9
   PubMed Web of Science ®Google Scholar
• Marshall SF, Clarke CA, Deapen D, et al. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 2010; 12:R4
   Google Scholar
• Balamurugan A, Im L, Reeve G, Mehta P, Bates JH. Incidence of female breast cancer in Arkansas: are we following the national trend?. J Ark Med Soc 2009;105:283–4, 286
   PubMedGoogle Scholar
• Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011;128:144–56
   PubMed Web of Science ®Google Scholar
• Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152–61
   PubMed Web of Science ®Google Scholar
• Bouchardy C, Usel M, Verkooijen HM, et al. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat 2010;120:519–23
   PubMed Web of Science ®Google Scholar
• Sharpe KH, McClements P, Clark DI, Collins J, Springbett A, Brewster DH. Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy. Eur J Cancer. 2010;46:937–43
   PubMed Web of Science ®Google Scholar
• Weedon-Fekjær H, Bakken K, Vatten LJ, Tretli S. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ 2012; 344:e299
   Google Scholar
• Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 2007;9:R28
   PubMed Web of Science ®Google Scholar
• Pollán M, Pastor-Barriuso R, Ardanaz E, et al. Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst 2009;101:1584–91
   PubMed Web of Science ®Google Scholar
• Crocetti E, Buzzoni C, Falcini F, et al. Disentangling the roles of mammographic screening and HRT in recent breast cancer incidence trends in Italy by analyses based on calendar time and time since screening activation. Breast J 2010;16:350–5
   PubMed Web of Science ®Google Scholar
• De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst 2010;102:1489–95
   PubMed Web of Science ®Google Scholar
• Silverman BG, Siegelmann-Danieli N, Braunstein R, Kokia ES. Trends in breast cancer incidence associated with reductions in the use of hormone replacement therapy. Cancer Epidemiol 2011;35:11–16
   PubMed Web of Science ®Google Scholar
• Séradour B, Allemand H, Weill A, Ricordeau P. Sustained lower rates of breast cancer incidence in France in 2007. Breast Cancer Res Treat 2010;121:799–800
   PubMed Web of Science ®Google Scholar
• Antoine C, Ameye L, Paesmans M, Rozenberg S. Update of the evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium. Maturitas 2012;72:317–23
   PubMed Web of Science ®Google Scholar
• Soerjomataram I, Coebergh JW, Louwman MW, Visser O, van Leeuwen FE. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?J Clin Oncol 2007;25:5038–9
   PubMed Web of Science ®Google Scholar
• Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Michels KB. The rise and fall of breast cancer rates. BMJ 2012;344:d8003
   Google Scholar
• Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490–500
   PubMed Web of Science ®Google Scholar
• Suhrke P, Mæhlen J, Zahl PH. Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway. Breast J 2012;18:549–56
   PubMed Web of Science ®Google Scholar
• Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004. Cancer Epidemiol Biomarkers Prev 2009;18:1763–9
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 2007;16:2773–80
   PubMed Web of Science ®Google Scholar
• Farhat GN, Walker R, Buist DS, Onega T, Kerlikowske K. Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 2010;28:5140–6
   PubMed Web of Science ®Google Scholar
• Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy?Ann N Y Acad Sci 2010;1205:268–76
   PubMed Web of Science ®Google Scholar
• Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685–92
   PubMed Web of Science ®Google Scholar
• Eurostat report, http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/
   Google Scholar
• Prentice RL, Huang Y, Hinds DA, et al. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18:3079–85
   PubMed Web of Science ®Google Scholar
• Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996;275:913–18
   PubMed Web of Science ®Google Scholar
• Sprague BL, Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. Breast Cancer Res Treat 2010;124:487–95
   PubMed Web of Science ®Google Scholar
• Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998–2005
   PubMed Web of Science ®Google Scholar
• Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778–86
   PubMed Web of Science ®Google Scholar
• Breen N, Cronin KA, Tiro JA, et al. Was the drop in mammography rates in 2005 associated with the drop in hormone therapy use?Cancer 2011;117:5450–60
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Fellemans C, Kroll M, Vandromme J. The menopause in Europe. Int J Fertil Womens Med 2000;45:182–9. Erratum in:Int J Fertil Womens Med 2000;45:296
   Web of Science ®Google Scholar
• Ahern CH, Cheng Y, Shen Y. Risk-specific optimal cancer screening schedules: an application to breast cancer early detection. Stat Biosci 2011;3:169–86
   PubMedGoogle Scholar
• Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009;12:514–24
   PubMed Web of Science ®Google Scholar
• Huot L, Couris CM, Tainturier V, Jaglal S, Colin C, Schott AM. Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int 2008;19:1047–54
   PubMed Web of Science ®Google Scholar
• Ena G, Rozenberg S. Issues to debate on the Women’s Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Hum Reprod 2003;18:2245–8
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al.;Women’s Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, et al.; LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708
   PubMed Web of Science ®Google Scholar
• Ghatge RP, Jacobsen BM, Schittone SA, Horwitz KB. The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res 2005;7:R1036–50
   PubMed Web of Science ®Google Scholar
• Gogoi R, Kudla M, Gil O, Fishman D. The activity of medroxyprogesterone acetate, an androgenic ligand, in ovarian cancer cell invasion. Reprod Sci 2008;15:846–52
   PubMed Web of Science ®Google Scholar
• Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20:2052–60
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 2012;21:1038–48
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Kuller LH, Prentice RL, et al.; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573–87
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, et al. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. J Natl Cancer Inst Monogr 2010;2010:181–6
   PubMedGoogle Scholar
• Goss PE, Ingle JN, Alés-Martínez JE, et al.; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381–91
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345: e6409
   PubMed Web of Science ®Google Scholar
• Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women’s Health Initiative trial. Hum Reprod 2004;19:741–56
   PubMed Web of Science ®Google Scholar
• Stahlberg C, Pedersen AT, Andersen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 2004; 91:644–50
   PubMed Web of Science ®Google Scholar
• Christante D, Pommier S, Garreau J, Muller P, LaFleur B, Pommier R. Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg 2008:196:505–11
   PubMed Web of Science ®Google Scholar
• Sener SF, Winchester DJ, Winchester DP, et al. The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg 2009;197:403–7
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al.; WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304:1684–92
   PubMed Web of Science ®Google Scholar
• Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468:98–102
   PubMed Web of Science ®Google Scholar
• Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468:103–7
   PubMed Web of Science ®Google Scholar
• Lee S, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the General Practice Research Database. BMJ Open 2011; 1(2):e000269
   Google Scholar
• Hiligsmann M, Bruyère O, Roberfroid D, et al. Trends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000–2007). Arthritis Care Res 2012;64:744–50
   Web of Science ®Google Scholar
• Mehta NK, Chang VW. Secular declines in the association between obesity and mortality in the United States. Popul Dev Rev 2011;37:435–51
   PubMed Web of Science ®Google Scholar
• Shao H, Breitner JC, Whitmer RA, et al.; for the Cache County Investigators. Hormone therapy and Alzheimer disease dementia: New findings from the Cache County Study. Neurology 2012; 79:1846–52
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Vandromme J, Antoine C. Postmenopausal hormone therapy: risks and benefits. Nature Rev Endocrinol 2013;9:216–27
   PubMed Web of Science ®Google Scholar